
-
Swiatek cruises, Osaka battles through in Montreal
-
Meta beats expectations sending share price soaring
-
Gaza civil defence says 30 killed in food queue by Israeli fire
-
Microsoft quarterly profits soar on AI and cloud growth
-
Airbus first-half profit climbs 85% to $1.7 bn
-
TikTok launches crowd-sourced debunking tool in US
-
'Ours forever': would-be Israeli settlers march on Gaza
-
Trump punishes Brazil with tariffs, sanctions over trial of ally Bolsonaro
-
US sprinter Kerley out of US trials
-
Ukraine will fix anti-graft law, minister tells AFP ahead of crucial vote
-
Tata Motors to buy Italy's Iveco for $4.4 bn
-
From skies over Gaza, Jordanian crew drops lifeline to civilians
-
US Fed holds firm against Trump pressure as divisions emerge
-
Michael Jackson's dirty sock sells for over $8,000 in France
-
Turkish city calls for help after heat tops 50C
-
Renault names Provost CEO after De Meo exit
-
Le Court makes history for Africa at women's Tour de France
-
Canada central bank holds rate steady citing US tariff 'threats'
-
Henry puts New Zealand in control of 1st Test against Zimbabwe
-
Stocks edge higher, dollar gains before tech earnings, Fed decision
-
Palestine Action wins bid to challenge terror ban in London court
-
EU urged to act on forests' faltering absorption of carbon
-
India secures return of ancient Buddhist gems
-
Stokes braced for 'emotional' tribute to late England batsman Thorpe
-
France's Luc Besson resurrects new 'romantic' Dracula
-
Trump hits India with 25% tariff and 'penalty' over Russia ties
-
Chinese sub discovers deepest-ever creatures 10 km undersea
-
Kingscote revels in being the 'villain' of Sussex Stakes shock
-
English cricket chiefs confirm sale of six Hundred franchises
-
Wirtz opens Liverpool account in friendly win in Japan
-
Marchand shatters record as US, Australia win more world gold
-
Thousands honour Ozzy Osbourne at UK hometown funeral procession
-
WHO chief says continuous medical aid into Gaza 'critical'
-
London court rules oligarch liable in $1.9 bn Ukraine loan scheme
-
England's Stokes out of India series decider with shoulder injury
-
Stocks diverge, dollar gains before tech earnings, Fed decision
-
India's Gill says Oval groundsman caused 'unnecessary' row
-
Physicists still divided about quantum world, 100 years on
-
Russia relieved as tsunami spares far east from major damage
-
'Can't believe it': Marchand shatters long-standing world record
-
French govt prepares new law to return colonial-era art
-
London court rules oligarch liable over $1.9 bn Ukraine loan scheme
-
Olympic biathlon champion confirmed dead after Pakistan mountaineering accident
-
German biathlete confirmed dead after accident on Pakistan mountain
-
Marchand smashes long-standing 200m medley world record
-
US economy returns to growth in second quarter on tariff turbulence
-
'All gone': Beijing villagers left with nothing after deadly floods
-
Aston Martin pares outlook as US tariffs weigh
-
Adidas says may hike US prices after tariff cost warning
-
GSK reports improved outlook despite US drug tariffs
RBGPF | -4.75% | 74.03 | $ | |
RYCEF | -2.14% | 13.1 | $ | |
CMSC | -0.04% | 22.6 | $ | |
NGG | -0.47% | 70.19 | $ | |
AZN | 3.41% | 76.59 | $ | |
GSK | 3.34% | 38.97 | $ | |
VOD | -0.45% | 11.06 | $ | |
BTI | 0.73% | 53.16 | $ | |
RIO | -4.67% | 59.49 | $ | |
RELX | -0.27% | 51.78 | $ | |
SCU | 0% | 12.72 | $ | |
BCC | -1.47% | 84.89 | $ | |
SCS | -1.74% | 10.33 | $ | |
BP | -2.2% | 32.25 | $ | |
JRI | 0.38% | 13.11 | $ | |
CMSD | -0.26% | 23.06 | $ | |
BCE | -0.55% | 23.53 | $ |

Canada health authority approves Pfizer's anti-Covid pill
Canada's health authority said Monday it has approved Pfizer's anti-Covid pill, Paxlovid, for adults at high risk of progressing to serious disease.
The oral treatment was approved after an "expedited review," Health Canada said in a statement on its website, adding that it would continue to monitor its safety and effectiveness.
"No drug, including PAXLOVID TM, is a substitute for vaccination," the statement added.
The drug, which comprises two types of tablet, is the first Covid-19 therapy which can be taken at home, and is potentially a huge step towards ending the pandemic.
"Today's announcement is particularly important as access to easy-to-use treatments could help to reduce the severity of Covid-19 in adults who become newly infected and are at high-risk of progressing to serious illness," said Theresa Tam, Canada's chief public health officer.
The approval comes as Canada, like many countries, has been struggling to contain the Omicron variant of Covid-19.
The French-speaking province of Quebec recently announced it would levy a tax on the unvaccinated, arguing they impose a burden on everyone else.
Paxlovid has so far been authorized in a handful of countries including the United States and Israel, while the European Union has allowed member states to use it ahead of formal approval as an emergency measure against Omicron.
Unlike vaccines, it does not target the ever-evolving spike protein which the coronavirus uses to invade cells.
It should therefore in theory be more variant-proof, and the company has said preliminary lab studies have backed up that hypothesis.
A.Gasser--BTB